NewCo News: Tocagen Gives High-Grade Glioma the One-Two Punch
By Catherine Shaffer
Wednesday, June 8, 2011
A Phase I/II trial of an unusual two-part therapeutic for brain cancer is under way, according to Tocagen Inc. The San Diego-based company has already dosed its first patient cohort, at the first dose, and received a green light from an independent data monitoring committee to progress to the second dose.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.